Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Deals - BioPharma Dive
Dec 18, 2024 · Novo Holdings’ purchase of Catalent set to close after regulators’ green light The $16.5 billion take-private deal can now be completed, along with Novo Nordisk’s related acquisition of three Catalent drug manufacturing plants.
Pfizer begins plan to challenge Shingrix with an mRNA vaccine
Feb 10, 2023 · Pfizer and partner BioNTech on Friday started the first human trial of a messenger RNA-based vaccine for shingles, believing their shot can be easier to take, and more efficiently produced, than the one available for use.. The trial is a two-part study that will enroll 900 healthy U.S. adults between the ages of 50 and 69. The first …
Rick Gonzalez, longtime AbbVie CEO, to step down in July
Feb 20, 2024 · The company has used large deals to help soften the blow. It bought Pharmacyclics for $21 billion to get a portion of the revenue from the blood cancer drug Imbruvica, and later paid $63 billion for Botox maker Allergan. But not every deal worked out so well, among them, was the $5.8 billion buyout of startup Stemcentrx for a …
GSK antibody drug reduces COPD attacks in trial | BioPharma Dive
Sep 6, 2024 · Dive Brief: GSK on Friday said its Nucala medicine succeeded in a Phase 3 study of patients with chronic obstructive pulmonary disease, offering the British drugmaker another shot at an expanded approval for the drug; The trial, known as MATINEE, included COPD patients suffering from chronic bronchitis and/or emphysema who were already taking inhaled therapies and showed evidence of a certain ...
Roche, following setbacks, turns to its next Alzheimer’s drug
Mar 11, 2024 · Dive Brief: Roche’s experimental Alzheimer’s disease drug trontinemab showed “best-in-class” potential based on its ability to quickly clear clumps of amyloid protein from the brains of patients enrolled in a small clinical trial, the company said Monday.; A majority of patients receiving the highest dose of the drug, which is specially designed to penetrate brain tissue, saw their ...
Lyophilized products are on the rise: Here's what you need to know
Jun 14, 2021 · "We were looking for an organization that could manage a very steep learning curve, hit the ground running and be flexible enough to make science and risk-based changes to the development program in real time," says Marc Viscogliosi, CEO of Spine BioPharma, which makes therapies for the treatment of pain and disability from chronic low back pain caused by degenerative disc disease.
10 clinical trials to watch in the first half of 2024
Jan 2, 2024 · 2023 could’ve been a turning point for Alnylam Pharmaceuticals. Though the pioneering developer of RNA interference medicines has already brought five drugs to market, it’s never been profitable. A new approval for one, Onpattro, in a genetic heart condition called transthyretin amyloidosis cardiomyopathy, was expected to finally change that. ...
Biotech News - BioPharma Dive
Jan 2, 2025 · The latest biotech news for biopharmaceutical professionals. Ionis gets a milestone approval; Another top FDA official to step down The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine.
Novartis raises forecasts as top drug sales beat Wall Street estimates
Apr 23, 2024 · Sales of Novartis drugs for heart failure, psoriasis and multiple sclerosis were stronger over the first three months of the year than anticipated, helping the Swiss pharmaceutical company report first quarter earnings Tuesday that beat Wall Street forecasts.. The drugmaker also raised its sales guidance for the year and now expects growth of …